G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
G1 Therapeutics (GTHX) reported $4.9 million in total revenue for Q3 2021, including $3.6 million from COSELA sales. The company has announced a supplemental sales force to enhance COSELA adoption, alongside the publication of a permanent J-code for billing. G1 plans to initiate two new Phase 2 trials in Q4 2021 to further explore trilaciclib’s immune-based action. An amended debt facility now extends its cash runway into 2024, with cash and equivalents totaling $212.1 million at quarter-end. However, Q3 net loss widened to $42.5 million from $11.7 million year-over-year.
- Achieved $3.6 million in net COSELA revenue for Q3 2021.
- Initiating two new Phase 2 trials for trilaciclib in Q4 2021.
- Amended debt facility extends cash runway into 2024.
- Cash and cash equivalents increased to $212.1 million.
- Net loss widened to $42.5 million in Q3 2021, compared to $11.7 million in Q3 2020.
- Sales impacted by execution and access challenges at key accounts.
- Achieved
of COSELA™ (trilaciclib) -
- Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication
of Permanent J-Code for COSELA -
- Initiation of Two New Phase 2 Trials Expected in the Fourth Quarter of 2021 to Further Investigate Trilaciclib’s Immune-Based Mechanism of Action (MOA) and Potential Benefits in Combination with an Antibody-Drug Conjugate (ADC) -
- Amended Debt Facility Extends Cash Runway into 2024 -
- Management to Host Webcast and Conference Call today at 8:30 AM ET -
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the third quarter ended September 30, 2021.
“The third quarter of 2021 was a period of rapid execution on initiatives designed to maximize the current and future opportunity of COSELA for patients, physicians, and investors,” said Jack Bailey, Chief Executive Officer of G1 Therapeutics. “We believe COSELA is a paradigm-changing drug. In just a matter of months, we have a number of important drivers such as exceptional reimbursement, high awareness and intention to treat, and excellent physician experience. However, our recent sales were impacted by less-than-optimal execution and access challenges at key accounts that treat up to 50 percent of patients diagnosed with small cell lung cancer. We are moving aggressively to address this, including by the deployment of a supplemental sales force to target these largest accounts. Longer term, our clinical programs are strategically designed to maximize the potential of trilaciclib and meaningfully improve the lives of people living with cancer, including our plans to initiate two new Phase 2 trials this quarter. We expect these studies to add to our broader development effort to demonstrate the potential of trilaciclib with therapies likely to be relevant in future treatment paradigms.”
Third Quarter 2021 and Recent Highlights
Financial
- Achieved Net COSELA™ (trilaciclib) Revenue of
$3.6 Million . - Ended the Third Quarter of 2021 with Cash and Cash Equivalents of
$212.1 million . - Upsized Debt Facility with Hercules Capital: The Hercules loan terms were amended to provide total commitments of
$150 million , with$100 million fully available as November 1, 2021. The Company’s current financial position is expected to be sufficient to fund G1’s operations and capital expenditures into 2024.
Commercial
- Announced New Supplemental COSELA Sales Force: G1 is in the process of hiring and training up to 15 people for the Company’s supplemental oncology sales force. The expansion will allow G1 to target top tier accounts to accelerate sales activities and help maximize the adoption of COSELA. The new G1 sales representatives will supplement the existing Boehringer Ingelheim oncology commercial team. (Press release here)
- Permanent J-code for COSELA Effective for Provider Billing as of October 1, 2021: The permanent J-code that was issued in July 2021 by the Centers for Medicare & Medicaid Services (CMS) is now effective for provider billing for all sites of care. All hospital outpatient departments, ambulatory surgery centers and physician offices in the United States now have one consistent Healthcare Common Procedure Coding System (HCPCS) code to standardize the submission and payment of COSELA insurance claims across Medicare, Medicare Advantage, Medicaid and commercial plans. The New Technology Add-on Payment (NTAP) for COSELA when administered to Medicare beneficiaries in the hospital inpatient setting is also effective. (Press release here)
Clinical
- Initiation of New Phase 2 Study of Trilaciclib to Support its Immune-based Mechanism of Action Expected in 4Q21: The Company confirmed its expectation to initiate a Phase 2 study of trilaciclib and chemotherapy in patients with early-stage triple negative breast cancer (TNBC) in the fourth quarter of 2021 to further investigate the role of trilaciclib in modulating the anti-tumor immune response.
- Initiation of New Phase 2 Study of Trilaciclib in Combination with an Antibody-Drug Conjugate (ADC) in Triple-Negative Breast Cancer Expected in 4Q21: G1 intends to initiate a Phase 2 single arm study of trilaciclib administered prior to an ADC in patients with unresectable locally advanced or metastatic TNBC in the fourth quarter of 2021.
- Received Fast Track designation for Trilaciclib for Use in in Triple-Negative Breast Cancer (TNBC): The U.S. Food and Drug Administration (FDA) granted Fast Track designation to trilaciclib for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer. Trilaciclib is currently being evaluated in PRESERVE 2, a pivotal Phase 3, randomized, double-blind, placebo-controlled study in patients receiving first- or second-line gemcitabine and carboplatin chemotherapy for TNBC. (Press release here)
- NSCLC Market Changes Drive Strategic Decision to Discontinue Phase 2 Trial of Trilaciclib in 2L/3L NSCLC and Shift Resources to New Phase 2 MOA and ADC Trials: The future treatment paradigm in 2L/3L NSCLC is expected to shift further away from docetaxel, the chemotherapy backbone in PRESERVE 4, suggesting minimal future market opportunity in this setting. As such G1 is discontinuing this trial and shifting those resources to support the new Phase 2 MOA and ADC trials
- Initiation of Investigator Initiated Study (IIS) of Trilaciclib in 1L Non-Small Cell Lung Cancer (NSCLC) Expected in 1Q22: As part of its broad investigator-initiated study program, G1 expects to support an IIS assessing the anti-tumor efficacy of trilaciclib in first-line NSCLC in combination with chemo and a checkpoint inhibitor.
Third Quarter 2021 Financial Results
As of September 30, 2021, cash and cash equivalents totaled
Total revenues for the third quarter of 2021 were
Operating expenses for the third quarter of 2021 were
Cost of goods sold expense for the third quarter of 2021 were
Research and development (R&D) expenses for the third quarter of 2021 were
Selling, general and administrative (SG&A) expenses for the third quarter of 2021 were
The net loss for the third quarter of 2021 was
Financial Guidance
Including the contribution from the amended Hercules agreement, the Company expects its current financial position to be sufficient to fund its operations and capital expenditures into 2024.
Webcast and Conference Call
G1 will host a webcast and conference call at 8:30 a.m. ET today to provide a corporate and financial update for the third quarter 2021 ended September 30, 2021. The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 4404009. A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.
About COSELA™ (trilaciclib) for Injection
COSELA (trilaciclib) was approved by the U.S. Food and Drug Administration on February 12, 2021.
Indication
COSELA™ (trilaciclib) is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
Important Safety Information
COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib.
Warnings and precautions include injection-site reactions (including phlebitis and thrombophlebitis), acute drug hypersensitivity reactions, interstitial lung disease (pneumonitis), and embryo-fetal toxicity.
The most common adverse reactions (>
This information is not comprehensive. Please click here for full Prescribing Information. https://www.g1therapeutics.com/cosela/pi/
To report suspected adverse reactions, contact G1 Therapeutics at 1-800-790-G1TX or call FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
G1 Therapeutics™ and the G1 Therapeutics logo and COSELA™ and the COSELA logo are trademarks of G1 Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to expectations for the commercial launch of COSELA (trilaciclib), the therapeutic potential of COSELA (trilaciclib), our ability to address less-than-optimal execution and access to top tier accounts, our ability to generate data to maximize trilaciclib’s applicability to future treatment paradigms, and our reliance on partners to develop and commercial licensed products. In addition, COSELA (trilaciclib) may fail to achieve the degree of market acceptance for commercial success, and the impact of pandemics such as COVID-19 (coronavirus), are based on the company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the company’s filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the company’s ability to complete a successful commercial launch for COSELA (trilaciclib); the company’s ability to complete clinical trials for, obtain approvals for and commercialize additional indications of COSELA and any of its product candidates other than COSELA (trilaciclib); the company’s initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a commercial-stage company; and market conditions. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
G1 Therapeutics Contacts:
Jen Moses
Chief Financial Officer
919-930-8506
jmoses@g1therapeutics.com
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com
Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
rlevine@g1therapeutics.com
| G1 Therapeutics, Inc. | ||||||
| Balance Sheet Data | ||||||
| (in thousands) | ||||||
| September 30, | December 31, | |||||
| 2021 | 2020 | |||||
| Cash and cash equivalents | $ | 212,089 | $ | 207,306 | ||
| Working Capital | $ | 206,144 | $ | 192,949 | ||
| Total Assets | $ | 243,497 | $ | 228,552 | ||
| Accumulated deficit | $ | (544,439 | ) | $ | (436,107 | ) |
| Total stockholders' equity | $ | 178,339 | $ | 177,351 | ||
| G1 Therapeutics, Inc. | |||||||||||||||||||||
| Condensed Statements of Operations | |||||||||||||||||||||
| (in thousands, except per share data) | |||||||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||
| Revenues: | |||||||||||||||||||||
| Product sales, net | $ | 3,576 | $ | - | $ | 6,717 | $ | - | |||||||||||||
| License revenue | 1,282 | 26,599 | 18,963 | 28,739 | |||||||||||||||||
| Total revenues | 4,858 | 26,599 | 25,680 | 28,739 | |||||||||||||||||
| Operating expenses: | |||||||||||||||||||||
| Cost of goods sold | 591 | - | 1,642 | - | |||||||||||||||||
| Research and development | 21,143 | 17,932 | 56,435 | 56,897 | |||||||||||||||||
| Selling, general and administrative | 24,268 | 18,412 | 72,474 | 44,230 | |||||||||||||||||
| Total operating expenses | 46,002 | 36,344 | 130,551 | 101,127 | |||||||||||||||||
| Loss from operations | (41,144 | ) | (9,745 | ) | (104,871 | ) | (72,388 | ) | |||||||||||||
| Other income (expense): | |||||||||||||||||||||
| Interest Income | 7 | 50 | 35 | 922 | |||||||||||||||||
| Interest Expense | (934 | ) | (757 | ) | (2,609 | ) | (1,022 | ) | |||||||||||||
| Other income (expense) | (76 | ) | (291 | ) | (208 | ) | (488 | ) | |||||||||||||
| Total other income (expense), net | (1,003 | ) | (998 | ) | (2,782 | ) | (588 | ) | |||||||||||||
| Loss before income taxes | (42,147 | ) | (10,743 | ) | (107,653 | ) | (72,976 | ) | |||||||||||||
| Income tax expense | 321 | 931 | 679 | 931 | |||||||||||||||||
| Net loss | $ | (42,468 | ) | $ | (11,674 | ) | $ | (108,332 | ) | $ | (73,907 | ) | |||||||||
| Net loss per share, basic and diluted | $ | (1.00 | ) | $ | (0.31 | ) | $ | (2.60 | ) | $ | (1.95 | ) | |||||||||
| Weighted average common shares outstanding, basic and diluted | 42,383,573 | 38,009,204 | 41,740,911 | 37,819,071 | |||||||||||||||||
FAQ
What were G1 Therapeutics' total revenues for Q3 2021?
How much net revenue did G1 Therapeutics generate from COSELA in Q3 2021?
What is the expected cash runway for G1 Therapeutics?
What is the focus of the new Phase 2 trials initiated by G1 Therapeutics?
What was G1 Therapeutics' net loss for Q3 2021?
